CUE - キュ―・バイオファ―マ (Cue Biopharma Inc.) キュ―・バイオファ―マ

 CUEのチャート


 CUEの企業情報

symbol CUE
会社名 Cue Biopharma Inc (キュ―・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.   キュ―・バイオファ―マは米国のバイオ医薬品企業。がんや自己免疫疾患を治療するヒト免疫系の薬剤の開発に従事する。同社の薬剤候補にはT細胞を改善するCUE-100シリ―ズ、排出されたT細胞を活性化するCUE-200シリ―ズを含む。また、腫瘍の自己免疫疾患の適応症に対処するためのプラットフォ―ムを提供する。本社所在地はマサチュ―セッツ州ケンブリッジ。   Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.
本社所在地 21 Erie St. Cambridge MA 02139 USA
代表者氏名 Daniel R. Passeri ダニエル・R・パスジェリ
代表者役職名 President Chief Executive Officer
電話番号 +1 617-949-2680
設立年月日 41974
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.cuebiopharma.com
nasdaq_url https://www.nasdaq.com/symbol/cue
adr_tso
EBITDA EBITDA(百万ドル) -29.83774
終値(lastsale) 7.2262
時価総額(marketcap) 145487006.7692
時価総額 時価総額(百万ドル) 141.13420
売上高 売上高(百万ドル) 0.36300
企業価値(EV) 企業価値(EV)(百万ドル) 95.34820
当期純利益 当期純利益(百万ドル) -30.27878
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cue Biopharma Inc revenues increased from $0K to $363K. Net loss increased 91% to $14.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing va increase from $4.1M to $8.4M (expense) General and administrative - Balancing increase from $1.3M to $2.7M (expense).

 CUEのテクニカル分析


 CUEのニュース

   Cue Biopharma to Present at the Jefferies Healthcare Conference  2022/06/01 12:00:00 GlobeNewswire
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the Jefferies Healthcare Conference being held June 8–10, 2022.
   Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting  2022/05/26 21:00:00 GlobeNewswire
BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in-person June 3–7 at the McCormick Place Convention Center in Chicago, Illinois and virtually.
   Hedge Fund and Insider Trading News: George Soros, Alan Howard, Ken Griffin, Bill Ackman, Elliott Management, Bridgewater Associates, Angelo Gordon & Co., Averill Partners, Cue Biopharma Inc (CUE), Noble Corporation (NE), and More  2022/05/25 17:23:09 Insider Monkey
The world''s largest hedge fund is sounding the alarm over a possible return to 1970s-style "stagflation," as the Federal Reserve moves to tame sky-high inflation.
   Elevation Oncology, Cue Biopharma top healthcare gainers, Verrica, PMV lead losers'' pack  2022/05/25 14:04:40 Seeking Alpha
Elevation Oncology ELEV +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences EVLO +13%. Verrica Pharmaceuticals VRCA -58%. PMV Pharmaceuticals (PMVP) -10%.
   FDA Accepts IND for Cue Biopharma''s CUE-102 in the treatment of Wilms'' Tumor 1 (WT1)  2022/05/11 14:40:46 Benzinga
Cue Biopharma, Inc. (NASDAQ: CUE ) received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of Wilms'' Tumor 1 (WT1)-positive recurrent/metastatic cancers. This IND acceptance enables the dose escalation of Phase 1 trial to start dosing at 1 mg/kg, supported by the safety and tolerability … Full story available on Benzinga.com
   Jet Edge Announces Cue Health Molecular COVID-19 Testing For Flight Crews and Worldwide Operations  2022/02/16 19:08:00 Kwhen Finance
   Aridis, Galapagos lead healthcare gainers; Epizyme, Cue Biopharma among losers  2022/01/27 15:03:00 Seeking Alpha
Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.
   Cue Health to Present at the 40th Annual J.P. Morgan Healthcare Conference  2022/01/05 21:01:00 Kwhen Finance
   Analysts Expect Cue Biopharma, Inc. (NASDAQ:CUE) Will Post Quarterly Sales of $6.50 Million  2021/12/19 07:32:42 ETF Daily News
Wall Street brokerages expect Cue Biopharma, Inc. (NASDAQ:CUE) to post $6.50 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cue Biopharmas earnings, with the highest sales estimate coming in at $10.85 million and the lowest estimate coming in at $2.16 million. Cue Biopharma reported sales of $480,000.00 [] The post Analysts Expect Cue Biopharma, Inc. (NASDAQ:CUE) Will Post Quarterly Sales of $6.50 Million appeared first on ETF Daily News .
   Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer  2021/12/15 13:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15th, 2021.
   Aridis, Galapagos lead healthcare gainers; Epizyme, Cue Biopharma among losers  2022/01/27 15:03:00 Seeking Alpha
Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.
   Cue Health to Present at the 40th Annual J.P. Morgan Healthcare Conference  2022/01/05 21:01:00 Kwhen Finance
   Analysts Expect Cue Biopharma, Inc. (NASDAQ:CUE) Will Post Quarterly Sales of $6.50 Million  2021/12/19 07:32:42 ETF Daily News
Wall Street brokerages expect Cue Biopharma, Inc. (NASDAQ:CUE) to post $6.50 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cue Biopharmas earnings, with the highest sales estimate coming in at $10.85 million and the lowest estimate coming in at $2.16 million. Cue Biopharma reported sales of $480,000.00 [] The post Analysts Expect Cue Biopharma, Inc. (NASDAQ:CUE) Will Post Quarterly Sales of $6.50 Million appeared first on ETF Daily News .
   Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer  2021/12/15 13:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15th, 2021.
   -$0.30 EPS Expected for Cue Biopharma, Inc. (NASDAQ:CUE) This Quarter  2021/12/04 19:58:41 Transcript Daily
Equities analysts predict that Cue Biopharma, Inc. (NASDAQ:CUE) will report earnings per share of ($0.30) for the current quarter, according to Zacks. Two analysts have made estimates for Cue Biopharmas earnings. The highest EPS estimate is ($0.20) and the lowest is ($0.40). Cue Biopharma posted earnings of ($0.37) per share during the same quarter last []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 キュ―・バイオファ―マ CUE Cue Biopharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)